[Glucagon secretion in patients with nephrotic syndrome in primary glomerulonephritis during the period of renal efficiency].
The performed studies covered 28 patients with nephrotic syndrome and 10 healthy individuals. The oral glucose tolerance test in 20 patients with nephrotic syndrome revealed glycemic values within the norm, and features of defective tolerance to glucose or diabetes in 8 subjects. Hyperglucagonemia was recorded in all the patients with increased glycemic values in the oral glucose tolerance test. It was found that hyperglucagonemia appeared in 70% of studied patients with normal glucose tolerance. All the groups of patients with nephrotic syndrome disclosed a decrease in glucagonemia, observed in normal subjects, in the course of oral glucose tolerance test as well as slower disappearance of glucagon from the circulatory system, which may be of certain significance in the occurrence of hyperglucagonemia. It has been ascertained that hyperglucagonemia may be one of the factors having influence upon a higher incidence rate of glucose tolerance abnormalities than in general population; can have a share in intensified catabolic processes, and also counteracts the effects of increased tissue absorption of glucose in patients with nephrotic syndrome. There has been a lower stimulating action of exogenic glucagon on insulin secretion in patients with nephrotic syndrome and hyperglucagonemia as compared to patients with normoglucagonemia and to healthy subjects.
Napierała
K
K
Kliniki Endokrynologii i Chorób Przemiany Materii Instytutu Chorób Wewnetrznych Pomorskiej Akademii Medycznej.
D000293:Adolescent; D000328:Adult; D005260:Female; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009402:Nephrosis, Lipoid / Q000503:physiopathology*; D010179:Pancreas / Q000378:metabolism*; D010186:Pancreatic Function Tests
D005934:Glucagon
Wydzielanie glukagonu u chorych z zespołem nerczycowym w przebiegu pierwotnych kłebkowych zapaleń nerek w okresie wydolności nerek.